Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice

Journal of Endocrinology

Volumn 213, Issue 3, 2012, Pages 285-291

  Inoue, Eriko ^a   Ichiki, Toshihiro ^a   Takeda, Kotaro ^a   Matsuura, Hirohide ^a   Hashimoto, Toru ^a   Ikeda, Jiro ^a   Kamiharaguchi, Aya ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CHOLESTEROL; GLUCOSE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CELL SIZE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEMODYNAMICS; HISTOLOGY; HORMONE ACTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; MACROPHAGE; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CELL SIZE; CHEMOKINE CCL2; DIET, HIGH-FAT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDIDYMIS; EPOPROSTENOL; GENE EXPRESSION; GLUCOSE INTOLERANCE; HEART RATE; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 84864308908     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0014     Document Type: Article

References (37)

1. Aguirre V, Uchida T, Yenush L, Davis R & White MF 2000 The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). Journal of Biological Chemistry 275 9047-9054.
2. Bays H, Mandarino L & DeFronzo R 2004 Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. Journal of Clinical Endocrinology and Metabolism 89 463-478.
3. Bruun JM, Lihn AS, Pedersen SB & Richelsen B 2005 Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. Journal of Clinical Endocrinology and Metabolism 90 2282-2289.
4. Camp HS, Ren D & Leff T 2002 Adipogenesis and fat-cell function in obesity and diabetes. Trends in Molecular Medicine 8 442-447.
5. Chen Y, Hanaoka M, Chen P, Droma Y, Voelkel NF & Kubo K 2009 Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysema. American Journal of Physiology. Lung Cellular and Molecular Physiology 296 L648-L656.
6. Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG & Clapp LH 2007 IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. Biochemical and Biophysical Research Communications 360 821-827.
7. Fujiwara K, Nagasaka A, Nagata M, Yamamoto K, Imamura S, Oda N, Sawai Y, Hayakawa N, Suzuki A & Itoh M 2004 A stable prostacyclin analogue reduces high serum TNF-alpha levels in diabetic patients. Experimental and Clinical Endocrinology & Diabetes 112 390-394.
8. Goya K, Otsuki M, Xu X & Kasayama S 2003 Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 52 192-198.
9. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, KarinM & Hotamisligil GS 2002 A central role for JNK in obesity and insulin resistance. Nature 420 333-336.
10. Hotamisligil GS, Shargill NS & Spiegelman BM 1993 Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 87-91.
11. Hotamisligil GS, Murray DL, Choy LN & Spiegelman BM 1994a Tumor necrosis factor alpha inhibits signaling from the insulin receptor. PNAS 91 4854-4858.
12. Hotamisligil GS, Budavari A, Murray D & Spiegelman BM 1994b Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. Journal of Clinical Investigation 94 1543-1549.
13. Hotamisligil GS, Arner P, Caro JF, Atkinson R & Spiegelman BM 1995 Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigation 95 2409-2415.
14. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF & Spiegelman BM 1996 IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 665-668.
15. Hwang JH, Stein DT, Barzilai N, Cui MH, Tonelli J, Kishore P & HawkinsM 2007 Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. American Journal of Physiology. Endocrinology and Metabolism 293 E1663-E1669.
16. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD et al. 1999 Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48 1113-1119.
17. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M et al. 2006 Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. Journal of Biological Chemistry 281 26602-26614.
18. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K et al. 2006 MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation 116 1494-1505.
19. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY & Diehl AM 2003 Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 343-350.
20. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294 2166-2170.
21. Ofei F, Hurel S, Newkirk J, Sopwith M & Taylor R 1996 Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45 881-885.
22. Ohta S, Nakamuta M, Fukushima M, Kohjima M, Kotoh K, Enjoji M & Nawata H 2005 Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates concanavalin A-induced liver injury in mice. Liver International 25 1061-1068.
23. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H et al. 1998 Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Journal of Clinical Investigation 101 1354-1361.
24. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A & Seeger W 2004 Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 102 139-153.
25. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM & Mortensen RM 1999 PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 4 611-617.
26. Sato N, Kaneko M, Tamura M & Kurumatani H 2010 The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 59 1092-1100.
27. Savage DB, Petersen KF & Shulman GI 2007 Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiological Reviews 87 507-520.
28. Shoelson SE, Lee J & Goldfine AB 2006 Inflammation and insulin resistance. Journal of Clinical Investigation 116 1793-1801.
29. Suganami T, Nishida J & Ogawa Y 2005 A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arteriosclerosis, Thrombosis, and Vascular Biology 25 2062-2068.
30. Tamura Y, Sugimoto M, Murayama T, Minami M, Nishikaze Y, Ariyasu H, Akamizu T, Kita T, Yokode M & Arai H 2010 C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. Journal of Atherosclerosis and Thrombosis 17 219-228.
31. Uysal KT, Wiesbrock SM, Marino MW & Hotamisligil GS 1997 Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389 610-614.
32. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews 21 697-738.
33. Watanabe M, Nakashima H, Mochizuki S, Abe Y, Ishimura A, Ito K, Fukushima T, Miyake K, Ogahara S & Saito T 2009 Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium. American Journal of Nephrology 30 1-11.
34. Weisberg SP, McCannD, Desai M, RosenbaumM, LeibelRL&Ferrante AWJr 2003 Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation 112 1796-1808.
35. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL & Ferrante AW Jr 2006 CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Journal of Clinical Investigation 116 115-124.
36. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA et al. 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 112 1821-1830.
37. Yamauchi T, Kamon J, Waki H, Terauchi Y, KubotaN, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N et al. 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7 941-946.